Long-term safety, tolerability, and efficacy of subcutaneous efgartigimod PH20 in generalized myasthenia gravis: final results from a phase 3 open-label extension study (ADAPT-SC+).
Meisel A, Antozzi C, Bhavaraju-Sanka R, De Bleecker JL, Huang W-Y, Jimenez R H, Verhamme FM, Jiang M, Liu L, Korobko D, et al.
Front Neurol. 2026; 17:1876344. PMID: 42699831.Abstract
